Gefitinib clinical trials

These findings resulted in the initiation of phase II trials employing gefitinib monotherapy in patients with recurrent non-small cell lung cancer the so-called IDEAL trials.

Study participants were randomized to mg or mg of gefitinib per day. Median survivals ranged between 6 and 8 months. Talk with your doctor and family members or friends about deciding to join a study.

To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. Try the modernized ClinicalTrials. Learn more about the modernization effort. Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information. Search for terms. Save this study. Warning You have reached the maximum number of saved studies Listing a study does not mean it has been evaluated by the U.

Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Last Update Posted : July 7, See Contacts and Locations. Study Description. Safety and tolerability of Apatinib in combination with Gefitinib will be assessed in the first portion Part A before proceeding to the second portion of this study Part B.

Drug Information available for: Gefitinib. FDA Resources. Arms and Interventions. Patients will be treated with Gefitinib, mg p. Outcome Measures.

MTD was determined by testing increasing doses up to mg daily qd on dose escalation cohorts 1 to 3 with 3 patients each. Lung Cancer. Epub Nov Epub Dec 1. Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study.

Epub Mar Asia Pac J Clin Oncol. Epub Apr Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. Epub Aug National Library of Medicine U.

National Institutes of Health U. Department of Health and Human Services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Non-Small Cell Lung Cancer. Phase 3. Study Type :. Interventional Clinical Trial. Actual Enrollment :. Study Start Date :. Actual Primary Completion Date :.

Actual Study Completion Date :. Experimental: 1 gefitinib. May 8, Key Record Dates.